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Background: Angiogenesis has been reported to be one of the contributory factors to the pathogenesis of
psoriasis vulgaris. This study aims to compare the expression of different angiogenesis growth factors namely (1) the
vascular endothelial growth factor (VEGF) subfamily: A, B, C, D and placenta growth factor (PlGF); (2) nerve growth
factor (NGF) and (3) von Willebrand factor (vWFr) in the skins of patients with psoriasis vulgaris and non-psoriatic
volunteers.
Results: Comparative immunohistochemistry study was performed on the paraffin-sectioned psoriatic and healthy
skins with the abovementioned markers. VEGF-C (p= 0.016) and NGF (p= 0.027) were expressed intensely in the
cases when compared with the controls. The NGF was the only marker that was solely expressed in the cases and
absent in all the controls.
Conclusion: The NGF (angiogenesis) and VEGF-C (lymphangiogenesis) might play a crucial role in the pathogenesis
of psoriasis vulgaris and could be researched further as potential new targeted therapies for psoriasis vulgaris.Background
Angiogenesis or neovascularization refers to the forma-
tion of new capillary vessels from the existing vascular
bed [1]. Angiogenesis was first reported in 1972 as a
contributory factor in the pathogenesis of psoriasis vul-
garis, replacing the initial reports of the disease being
purely immunologic in nature [2]. Psoriasis has been
studied in the light of it being angiogenic in nature since
then [3]. Four-fold increase of endothelial microvascular
bed was seen in the psoriatic skin but not in normal skin,
thus signifying the importance of angiogenesis in psoria-
sis [4]. Dermal microvascular expansion with abnormal
orientation and dilatation of capillaries in the biopsies of
the psoriatic skin revealed that the disease was angiogen-
esis dependent [5]. Other supporting evidences include
the increased of blood flow observed in the skin biopsy
peripheral to the psoriatic lesion that was obtained with
laser doppler fluxmetry [6], the increased of the micro-
vasculature of the lesion seen in audioradiograph [7] and* Correspondence: siawcheok_liew@imu.edu.my
1Department of Postgraduate Studies and Research, International Medical
University, Kuala Lumpur, Malaysia
Full list of author information is available at the end of the article
© 2012 Liew et al; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orthe elongated capillary loops in psoriasis as reported in
an ultra-structural study [8].
The keratinocytes in the psoriatic skin lesions were recog-
nized as a source of pro-angiogenic cytokines which induce
angiogenesis, namely the vascular endothelial growth factor
(VEGF). Other commonly recognized cytokines were endo-
thelial cell stimulating angiogenesis factor (ESAF), tumour
necrosis factor-α (TNF-α) and platelet derived growth fac-
tors (PDGF) [9-14].
The VEGF-A has four isoforms - (VEGF121, VEGF165,
VEGF189 and VEGF206) [9,15] and was structurally related
to the VEGF-B, VEGF-C, VEGF-D and placenta growth
factor (PlGF) [16]. The role of VEGF-A, formally known
as VEGF, in angiogenesis was well established [17-19]. The
VEGF-A regulates the growth of the vascular endothelial
cells of the arteries, veins and the lymphatics [20]. The
VEGF-A was involved in vasculogenesis and angiogenesis
during the embryonic and early postnatal development
[20-22], skeletal growth [23], wound healing [24-26] and
ovarian angiogenesis [27-29]. Up-regulation of the VEGF-
A mRNA expression was reported in tumours of the lung
[30], thyroid [31], breast [32], liver [33], kidney and blad-
der [34] and the female reproductive tracts [35,36]. The
VEGF-A has been associated with skin inflammation and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.





Age, mean± SD 47.94 ± 10.55 42.33 ± 22.38
Gender
Male, n (%) 10 (59%) 4 (67%)
Female, n (%) 7 (41%) 2 (33%)
Race
Chinese, n (%) 4 (24%) 1 (17%)
Indian, n (%) 4 (24%) 1 (17%)
Malay, n (%) 9 (52%) 4 (66%)
PASI, mean ± SD 7.25 ± 4.78 N/A
Smoking, n (%) 2 (11.8%) 0 (0)
BMI 25.94 ± 4.80 20.6 ± 2.69
Additional Co-morbidities
(SLE, Chron’s, Ulcerative colitis,
Rheumatoid Arthritis).
NIL NIL
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the psoriatic skin expressed the VEGF-A receptors 1 and
2 on their surfaces. The VEGF-A secreted by the kerati-
nocytes was able to bind to these receptors and activate
the signaling pathway via an autocrine manner [38,39].
The VEGF-A expression at the basal keratinocytes showed
psoriatic-like skin inflammation with increased tortousity
and branching of dermal blood vessels in a mouse model
[40,41].
The VEGF-B (188 amino acids) was found abundantly
in muscle and myocardium. The VEGF-B stimulated the
growth of the vascular endothelial cells and involved in
embryogenic angiogenesis [42,43]. The VEGF-C (399 amino
acids) stimulated the growth of human lung endothelial
cells and was involved in lymphangiogenesis [44,45]. Similar
to VEGF-C, VEGF-D is lymphangiogenic in nature [46,47].
The placenta growth factor (PlGF) was expressed during
ischaemia, inflammation, wound healing and tumorigen-
esis [48,49]. Though the VEGF-A has been well-associated
in the pathogenesis of psoriasis, the structurally related
subfamily (VEGF-B, C, D and PlGF) immunohistochemis-
try expression in psoriasis is still unknown. Differential
immunohistochemistry expression of these subfamily mole-
cules with the VEGF-A is not documented previously.
The NGF was identified as a novel angiogenic mol-
ecule, be it in the physiological (wound healing) [50] or
pathological conditions (ischaemia and tumour growth)
[51-53]. The NGF was highly expressed in blood vessels
of hypertensive rats [54], hearts of ischaemic rats [55]
and brains of hypertensive rats [56]. The von Willebrand
factor (vWFr) was involved in the endothelial cell activa-
tion which leads to tumours angiogenesis [57].
This study aims to investigate the immunohistochem-
istry expression of the vascular endothelial growth factor
(VEGF-A) in comparison with its subfamily i.e. VEGF-B,
C, D and PlGF, and also with the recently identified
angiogenesis growth factors (NGF and vWFr) in the
cases and controls. The comparative levels of immuno-
histochemistry expression of the VEGF (subfamily A, B,
C, D and PlGF), NGF and vWFr in psoriasis vulgaris are
still unknown. We investigated the expression of these
angiogenesis growth factors in psoriasis vulgaris patients
and healthy controls. The association of these angiogen-
esis growth factors with the pathogenesis of psoriasis
vulgaris will be of great importance in the understanding




The cases for this retrospective study were recruited from
the Dermatology Department of Hospital Kuala Lumpur,
Kuala Lumpur and Tuanku Ja’afar Hospital, Seremban,
Malaysia. All the patients with psoriasis vulgaris (n= 17)were clinically examined and diagnosed by the dermatolo-
gist. Healthy controls (n= 6) were recruited from the
Orthopaedic Department of Tuanku Ja’afar Hospital,
Seremban. The cases and controls were well-informed
about the nature of this study and the participations
were voluntary. Informed consent was obtained from each
of the participants. The cases were psoriasis vulgaris
patients that were not receiving any form of systemic or
phototherapy. Topical therapy had been discontinued for
2 weeks prior to the procedures of obtaining the biopsies.
Only topical emollients were used. A 6 mm punch biopsy
was obtained from each subject and fixed in 10% buffered
formalin solution. The protocol of this study was designed
according to the Declaration of Helsinki and was approved
by the ethics committee of our University. The character-
istics of the cases and controls are summarized in Table 1.Immunohistochemistry
The fixed biopsies were processed, embedded in paraffin
and sectioned at 4 μm with a microtome (Leica RM 2135,
Germany). The sections were placed on poly-L-lysine
coated slides and were incubated at 60°C for 30 minutes
for proper adherence and drying. The sections were depar-
raffinized by subjecting to 3 changes of xylene substitute
(Sigma, USA) for 3 minutes each. The sections were rehy-
drated in descending concentration of alcohols gradually
from 100% to 20% and lastly in water (3 minutes each).
Antigen retrieval procedure was performed using a micro-
wave in citrate buffer (pH 6.0) for 15 minutes. The non-
specific areas of the sections were blocked with blocking
solution (1: 10; Kirkegaard & Perry Lab (KPL), Maryland
USA) for 4 minutes and followed by swine normal serum
(1: 20; Dako Cytomation, Denmark). The sections were
either incubated with rabbit anti-VEGF-A (polyclonal; 1:
25; Millipore, CA, USA), mouse anti-VEGF-B (monoclonal;
























Figure 1 The mean angiogenesis markers staining score for
cases (n = 17).
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1: 25; Abcam, Camb, UK), rabbit anti-VEGF-D (polyclonal;
1: 25; Abcam, Camb, UK), rabbit anti-NGF (polyclonal; 1:
25; Abcam, Camb, UK), rabbit anti-PlGF (polyclonal; 1: 25;
Abcam, Camb, UK) and rabbit anti-vWFr (polyclonal; 1: 25;
Abcam, Camb, UK) overnight at 4°C in a wet chamber
respectively. After the incubation, the slides were washed
with phosphate buffered saline (PBS) for 10 minutes before
incubation with horseradish peroxidase conjugated anti-
mouse or anti-rabbit immunoglobulins (1: 200) respect-
ively for 2 hours at room temperature. The slides were
washed with PBS for 10 minutes and incubated with True-
Blue peroxidase substrate (KPL, Maryland USA) for 10
minutes. The substrate was washed away with ultra-pure
water for 3 minutes and the samples were counterstained
with KPL Orcein for 3 minutes. The slides were then
rinsed with ultra-pure water, dehydrated in ascending
concentration of alcohols every 3 minutes, dried, mounted
with Depex and observed under a compound microscope
(Nikon, Japan) at 40X, 100X, 200X and 400X magnifica-
tions. The intensity of the staining was scored: negative,
weak, moderate and strong. The scores were 0 for nega-
tive, 1 for weak, 2 for moderate and 3 for strong staining
patterns. The mean score for each growth factor was
calculated.0
0.5





Figure 2 The mean angiogenesis markers staining score for
controls (n = 6).Statistical analysis
An Independent T-test and subsequent Mann–Whitney-U
test were used to analyze the staining scoring of these
markers on cases and controls. Pearson’s correlation was
used to determine the correlation of the Psoriatic Area
and Severity Index (PASI) with the intensity of the stain-
ing for each marker. P values of less than 0.05 were con-
sidered statistically significant.Results
PASI classification
The average PASI score for the cases was 7.247 ± 4.780.
The age (mean) for the cases was 47.94 years and for the
controls was 42.33 years.Immunohistochemistry
The mean scores (± standard deviation) for VEGF-A,
VEGF-B, VEGF-C, VEGF-D, NGF, PlGF and vWFr immu-
noreactivities in cases were 1.76± 1.03, 0.00, 1.59 ± 1.12,
0.35 ± 0.61, 1.24 ± 1.25, 1.12 ± 1.32 and 0.65± 1.06 respect-
ively (Figure 1). The mean scores (± standard deviation)
for VEGF-A, VEGF-B, VEGF-C, VEGF-D, NGF, PlGF
and vWFr staining in controls were 1.83 ± 0.98, 0.00,
0.33 ± 0.52, 0.33 ± 0.52, 0.00, 0.33 ± 0.82 and 1.67 ± 0.52
respectively (Figure 2). The immunohistochemistry stain-
ing of the abovementioned markers on psoriasis vulgaris
skin were shown in Figure 3.There was no significant correlation between the ex-
pression of these growth factors with PASI scores:
VEGF-A (p= 0.399), VEGF-B (negative staining for cases
and controls), VEGF-C (p= 0.232), VEGF-D (p= 0.216),
NGF (p= 0.177), PlGF (p= 0.404) and vWFr (p= 0.169).
An Independent T-test and subsequent Mann Whitney
U test were performed for multiple comparisons between
the expression of these markers, cases and controls. The
intensity of staining VEGF-C (p= 0.016) was significantly
higher in the cases when compared with the controls.
Mann Whitney U test showed similar result (p= 0.016).
Significant intensity in expression of the NGF was
observed in cases compared with controls (p= 0.027, In-
dependent T-test; p= 0.020, Mann Whitney U test). The
other growth factors did not show any significant differ-
ences in the intensities of their staining between cases
and controls. The VEGF-A (p= 0.889), VEGF-B (negative
staining for cases and controls), VEGF-D (p= 0.945),
PlGF (p= 0.189) and interestingly vWFr were signifi-






Figure 3 Immunohistochemistry staining of the skins of patients with psoriasis vulgaris. (A) Strong VEGF-A expression in the epidermis and
dermis of the psoriatic skin at 200 x magnification. (B) No staining of VEGF-B in all layers of the psoriatic skin at 200 x magnification. (C) Strong
staining of VEGF-C in the dermal layer of the psoriatic skin at 200 x magnification. (D) Moderate staining of VEGF-D in dermal layer of the psoriatic
skin at 100 x magnification. (E) Moderate staining of PlGF in all layers of the psoriatic skin at 200 x magnification. (F) Strong staining of NGF in
dermal layer of psoriatic skin at 200 x magnification. (G) Weak staining of vWFR in the epidermis of the psoriatic skin at 200 x magnification. Note:
blue to purple indicated positive immunoreactivities with red as counterstain. (H) Haematoxylin and eosin (H&E) staining of the psoriatic skin at
200 x magnification.
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The mean homocysteine level in the cases was 16.41±
3.90 μmol/L. No statistically significant correlation be-
tween these markers and homocysteine levels in cases:
VEGF-A (p=0.853), VEGF-B (negative staining for cases
and controls), VEGF-C (p=0.139), VEGF-D (p=0.637),
NGF (p=0.374), PlGF (p=0.795) and vWFr (p=0.152).
Discussion
Cutaneous angiogenesis occurs during the normal physio-
logical stages of hair growth [58] and so could angiogen-
esis be found in pathological cutaneous conditions such as
malignant melanoma [59] and psoriasis [60]. Epidermal
keratinocytes have been identified mainly as the source of
the VEGF, PlGF, NGF and vWFR that contribute to psoria-
sis angiogenesis. The VEGF-C and VEGF-D are expressed
by the lymphatic endothelium contributing to lymphan-
giogenesis [61]. The VEGF-A has been well-established as
an angiogenesis factor in psoriasis vulgaris but the com-
parative expressions of its subfamily i.e. the VEGF-B,
VEGF-C, VEGF-D and PlGF with VEGF-A were lacking.
The newly discovered angiogenesis growth factors’ (NGF
and vWFr) expression in psoriasis vulgaris in comparison
with the VEGF family has never been documented.
No significant difference in the expression of VEGF-A
(p= 0.889) between the cases and controls was observed.
The VEGF-A was expressed in the keratinocytes of the
skins in the cases and was expressed in the dermal layer
of the skins in the controls. In the cases, the VEGF-A
was expressed in the keratinocytes of the epidermis and
some fibroblasts of the dermal layer. Henno et al. [62,63]
reported in both these studies, the expression of VEGF-
A mRNA was significantly increased in the psoriasis
patients when compared to the controls. Bhushan et al.
[64] reported that VEGF is produced predominantly by
the keratinocytes, far lesser extent by the fibroblast.
Creamer et al. [65] reported that the VEGF-A enhances
vascular permeability in eczema patients in response to
inflammation. Therefore, the increase of the expression
of the VEGF in the controls could be due to the inflam-
matory process subsequent to orthopaedic trauma.
The NGF was significantly expressed (p=0.027) solely in
the skin of the psoriatic patients compared with healthy
controls in the present study. Similar finding was reported
by Raychaudhuri et al. [66] who compared the expression
of the NGF in psoriasis vulgaris and lichen planus in
human. Fantini et al. [67] reported tissue extracts obtained
from psoriasis vulgaris patients showed higher levels of the
NGF compared with healthy controls. The role of NGF on
the development of psoriasis is still poorly understood
though related to neurogenic inflammatory nature of the
NGF postulation [66]. The NGF is a pleiotropic factor act-
ing both on the neuronal and vascular levels [68]. There-
fore, angiogenic nature of the NGF could have contributedto the high levels of the NGF seen in the psoriatic skin
compared with the controls. The significant association
between the NGF expression and psoriasis in comparison
to the other angiogenesis growth factors investigated in
this study may suggest the potential use of the NGF as an
indicator for the development of psoriasis vulgaris. Unlike
the VEGF-A, the expression of nerve growth factor was
very specific in psoriatic skin. Therefore, would a new tar-
geted therapy for the NGF be the future research area for
psoriasis vulgaris?
In this study we also found that the VEGF-C intensity of
staining were significantly (p=0.016) higher in the psori-
atic skin compared with the normal skin. Henno et al.
[62,63] reported the significant expression of mRNA in the
cases compared to the controls. The VEGF-C expression
revealed the role of lymphangiogenesis in psoriasis vul-
garis. Lazarovici et al. in his article “cross talk between
NGF and VEGF” stated expression of the NGF and the
VEGF resulted in the activation of two common intracel-
lular signaling cascades, trkA for the NGF and VEGFR-2
for the VEGF in endothelial cells that were involved in the
proliferation and survival of these cells. Therefore, there
was a probability of the concerting effects of the NGF and
VEGF in controlling angiogenesis processes [69]. Perhaps,
the same theoretical principle could also be researched
further on the synergistic interplay between the NGF and
the VEGF-C. A new drug discovery study would probably
target both the VEGF-C and NGF activities.
Another interesting finding would be the significant
higher intensity of staining of the VEGF-C (p=0.016) in
the psoriasis vulgaris skin compared with the controls, but
not for the VEGF-D (p=0.945) although both are lym-
phangiogenesis in nature and closely related structurally
[42]. Perhaps similar to previous speculation, the discrep-
ancies in the results could be due to the different tissue
distribution, i.e. the VEGF-C found mainly in heart, pla-
centa, ovary and small intestine whereas the VEGF-D was
commonly found in the lungs. Otherwise, could there be
another lymphangiogenesis receptor specific to the VEGF-
C cutaneously that was not receptive for the VEGF-D un-
like the conventional Flt-4 receptor that was shared be-
tween the two?
Conclusion
In conclusion, this study involved a small sample size and
showed a significant finding on the contribution of the
NGF and the VEGF-C in the pathogenesis of psoriasis vul-
garis. A bigger pool of samples could be used in future to
look at the association of NGF with psoriasis vulgaris and
to research further on the angiogenesis pathways of NGF
on psoriasis vulgaris. The same may also be investigated
for the VEGF-C. The interplay of the NGF and the VEGF-
C could also be investigated and the expansion of know-
ledge in the synergistic interplay pathway of the NGF and
Liew et al. BMC Research Notes 2012, 5:201 Page 6 of 7
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garis would prove useful for the development of future
therapeutic agent against the signaling cascades mediated
by the NGF and VEGF-C.
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